* Press release – Ariad presents updated long-term follow-up
results from the phase 1/2 trial on investigational drug
Brigatinib at 2016 ESMO meeting
The post REFILE-BRIEF-Ariad Pharma’s Brigatinib’s safety profile similar with longer follow-up appeared first on NASDAQ.